Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930321 | 1.00 | PPARG (0.64) | PPARGPPARA | |
| SCHEMBL28494551 | 0.99 | PPARG (0.63) | PPARGPPARA | |
| SCHEMBL29930451 | 0.99 | PPARG (0.63) | PPARGPPARA | |
| SCHEMBL1719558 | 0.96 | PPARG (0.70) | PPARGPPARA | |
| Tetrahydrofuran SCHEMBL28503087 | 0.94 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL1720775 | 0.94 | PPARG (0.67) | PPARGPPARA | |
| SCHEMBL29930546 | 0.92 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL1721006 | 0.92 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL5065101 | 0.89 | PPARG (0.67) | PPARGPPARA | |
| SCHEMBL1720151 | 0.89 | PPARG (0.61) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112479977-B | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2022-07-19 | — | — | CN | claimed |
| CN-112479977-A | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2021-03-12 | — | — | CN | claimed |
| CN-107868032-B | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2020-12-15 | — | — | CN | claimed |
| US-20200031771-A1 | SUBSTITUTED PHENYLPROPIONIC ACID ENANTIOMER AND MANUFACTURING METHOD, COMPOSITION, AND APPLICATION OF SAME | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-01-30 | — | — | US | claimed |
| EP-3521275-A1 | SUBSTITUTED PHENYLPROPIONIC ACID ENANTIOMER AND MANUFACTURING METHOD, COMPOSITION, AND APPLICATION OF SAME | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-08-07 | — | — | EP | claimed |
| CN-112479977-B | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-112479977-A | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-107868032-B | Substituted phenylpropionic acid compound enantiomer, and preparation method, composition and application thereof | 深圳微芯生物科技股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-20200031771-A1 | SUBSTITUTED PHENYLPROPIONIC ACID ENANTIOMER AND MANUFACTURING METHOD, COMPOSITION, AND APPLICATION OF SAME | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| EP-3521275-A1 | SUBSTITUTED PHENYLPROPIONIC ACID ENANTIOMER AND MANUFACTURING METHOD, COMPOSITION, AND APPLICATION OF SAME | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-1569904-B1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2012-01-11 | — | — | EP | disclosed |
| EP-1569904-A4 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCE (CN) | 2008-04-16 | — | — | EP | disclosed |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | LU XIAN-PING | 2008-02-28 | — | — | US | disclosed |
| US-7268157-B2 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-09-11 | — | — | US | disclosed |
| EP-1569904-A1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | Shenzhen Chipscreen Biosciences Ltd. (CN) | 2005-09-07 | — | — | EP | disclosed |
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-22 | — | — | US | disclosed |
| WO-2004048333-A1 | SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031771-A1 | SUBSTITUTED PHENYLPROPIONIC ACID ENANTIOMER AND MANUFACTURING METHOD, COMPOSITION, AND APPLICATION OF SAME | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
| US-20040142921-A1 | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
| US-20080051321-A1 | Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.